Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients

Alicja Wiercińska-Drapalo1, Robert Flisiak, Jerzy Jaroszewicz

  • 1Department of Infectious Diseases, Medical University of Bialystok, Bialystok, Poland. alicja@priv.onet.pl

Viral Immunology
|March 17, 2004
PubMed

Transforming growth factor-beta(1) (TGF-beta(1)) is a pleiotropic cytokine with a variety of effects on a wide range of cells in the immune system. Evidence suggests that TGF-beta(1) is also involved in the pathogenesis of human immunodeficiency virus type 1 infections. The aim of this study was to explore possible relationships between circulating TGF-beta(1) and immune as well as clinical HIV infection parameters with special impact on disease progression. TGF-beta(1) concentrations were measured by ELISA in the plasma of 66 patients in different stages of HIV infection and 20 healthy controls. HIV infection resulted in a significant increase of plasma TGF-beta(1) concentration compared to healthy individuals (11.4 +/- 6.8 vs. 6.1 +/- 1.5 ng/mL, p < 0.01). TGF-beta(1) values showed a significant negative correlation with CD4 cells count (r = -0.42, p = 0.001), as well as with CD8 cells count (r = -0.031, p < 0.05). Moreover, patients with the symptomatic phase of HIV infection presented an almost twofold increase of plasma TGF-beta(1) concentration in comparison to asymptomatic patients and healthy individuals. Our results demonstrate the relationship between TGF-beta(1) concentrations and HIV infection advancement with marked elevation in the late stages of the disease. These findings support in vitro observations suggesting an important, immunosuppressive role of TGF-beta(1) in HIV infection pathogenesis.

Related Concept Videos

TGF - &#946; Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...